CA2049964A1 - Proteines hybrides de la proteine de liaison de c4 - Google Patents
Proteines hybrides de la proteine de liaison de c4Info
- Publication number
- CA2049964A1 CA2049964A1 CA002049964A CA2049964A CA2049964A1 CA 2049964 A1 CA2049964 A1 CA 2049964A1 CA 002049964 A CA002049964 A CA 002049964A CA 2049964 A CA2049964 A CA 2049964A CA 2049964 A1 CA2049964 A1 CA 2049964A1
- Authority
- CA
- Canada
- Prior art keywords
- c4bp
- protein
- polypeptide
- human
- multimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47088890A | 1990-01-26 | 1990-01-26 | |
US470,888 | 1990-01-26 | ||
PCT/US1991/000567 WO1991011461A1 (fr) | 1990-01-26 | 1991-01-28 | Proteines de fusion de proteines liantes c4 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2049964A1 true CA2049964A1 (fr) | 1991-07-27 |
Family
ID=23869471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002049964A Abandoned CA2049964A1 (fr) | 1990-01-26 | 1991-01-28 | Proteines hybrides de la proteine de liaison de c4 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0465633A1 (fr) |
JP (1) | JPH04506460A (fr) |
AU (1) | AU7328891A (fr) |
CA (1) | CA2049964A1 (fr) |
WO (1) | WO1991011461A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05508779A (ja) * | 1991-03-12 | 1993-12-09 | バイオジェン,インコーポレイテッド | リンパ球機能関連抗原3のcd2結合ドメイン |
MX9203138A (es) * | 1991-03-12 | 1992-09-01 | Biogen Inc | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5869624A (en) * | 1993-03-26 | 1999-02-09 | Progenics Pharmaceuticals, Inc. | HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof |
US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
FR2736916B1 (fr) | 1995-07-21 | 1997-09-19 | Univ Paris Curie | Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp |
WO1999044625A1 (fr) | 1998-03-03 | 1999-09-10 | John Hopkins University | Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement |
JP2002512261A (ja) * | 1998-04-15 | 2002-04-23 | ベルクター,ヴォルフガンク | Hiv感染を治療するためのcd4放射免疫薬 |
AU4770300A (en) * | 1999-05-14 | 2000-12-05 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1419236A4 (fr) | 2001-07-24 | 2005-08-03 | Biogen Idec Inc | Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2 |
AU2003219732A1 (en) * | 2002-02-11 | 2003-09-04 | Institut De Recherches Cliniques De Montreal | Oligomeric molecules and uses thereof |
EP1529109A2 (fr) * | 2002-08-14 | 2005-05-11 | Avidis SA | Production de proteines de fusion multimeres utilisant un echafaudage c4bp |
CA2494971A1 (fr) * | 2002-08-14 | 2004-02-26 | Avidis Sa | Complexes multimeres d'antigenes et d'adjuvants |
JP2007528210A (ja) * | 2003-08-12 | 2007-10-11 | アヴィディス エスアー | C4bpコアタンパク質及び単量体抗原を含む生成物及びその使用 |
WO2005051414A1 (fr) * | 2003-11-26 | 2005-06-09 | Avidis Sa | Utilisation de la zone nucleique c4bp comme agoniste de cd40 |
WO2005077976A2 (fr) * | 2004-02-13 | 2005-08-25 | Avidis Sa | Domaines bispirales |
EP1750747A1 (fr) | 2004-05-07 | 2007-02-14 | Astellas US LLC | Polypeptide lfa-3 soluble destine a traiter de troubles viraux |
EP1790358A1 (fr) * | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Constructions protéiques concues pour cibler et lyser des cellules |
EP1795540A1 (fr) * | 2005-11-30 | 2007-06-13 | Imaxio | Complexes multiples d'antigènes et d'un adjuvant |
GB0918154D0 (en) * | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
EP2557089A2 (fr) * | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions et procédés d'immunomodulation |
EP3273990A4 (fr) | 2015-03-24 | 2018-11-14 | Fred Hutchinson Cancer Research Center | Glycoprotéines d'enveloppe du virus de l'immunodéficience humaine multimérisées et ingéniérisées et leurs utilisations |
WO2017083545A1 (fr) | 2015-11-10 | 2017-05-18 | Fred Hutchinson Cancer Research Center | Leurres nkg2d |
US11707505B2 (en) | 2019-11-15 | 2023-07-25 | King Faisal Specialist Hospital & Research Centre | VCP and factor H as viral entry inhibitors |
-
1991
- 1991-01-28 WO PCT/US1991/000567 patent/WO1991011461A1/fr not_active Application Discontinuation
- 1991-01-28 AU AU73288/91A patent/AU7328891A/en not_active Abandoned
- 1991-01-28 EP EP91903951A patent/EP0465633A1/fr not_active Withdrawn
- 1991-01-28 CA CA002049964A patent/CA2049964A1/fr not_active Abandoned
- 1991-01-28 JP JP3504137A patent/JPH04506460A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU7328891A (en) | 1991-08-21 |
JPH04506460A (ja) | 1992-11-12 |
EP0465633A1 (fr) | 1992-01-15 |
WO1991011461A1 (fr) | 1991-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2049964A1 (fr) | Proteines hybrides de la proteine de liaison de c4 | |
Lasky et al. | Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor | |
Zettlmeissl et al. | Expression and characterization of human CD4: immunoglobulin fusion proteins | |
EP0325262B1 (fr) | Gènes clonés encodant des protéines fusionnées Ig-CD4 et leur utilisation | |
JP4642035B2 (ja) | Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ | |
EP0394827A1 (fr) | Polypeptides chimériques de CD4-immunoglobuline | |
KR100547049B1 (ko) | 바이러스 감염증 치료를 위한 조성물 및 방법 | |
CA1330038C (fr) | Methode et compositions pour l'utilisation des polypeptides env de vih et anticorps diriges contre ces polypeptides | |
EP0687183A1 (fr) | Composition synergique d'une proteine a base de cd4 et d'un anticorps dirige contre le vih-1, et procedes d'utilisation | |
NZ226040A (en) | T-cell specific antigens, dna and pharmaceutical compositions | |
EP1340769B1 (fr) | Chimères de CD4-gamma2 et de CD4-IgG2 | |
EP0414178A2 (fr) | Polypeptides CD4 de primates non humains et molécules CD4 humaines susceptibles d'être glycosylées | |
CA2078545A1 (fr) | Polypeptides de l'enveloppe de vih | |
IL91070A (en) | Cytotoxic agents against certain viral infections | |
WO1992013559A1 (fr) | CHIMERES DE CD4-GAMMA1 ET DE CD4-IgG1 | |
Howie et al. | Synthetic peptides representing discontinuous CD4 binding epitopes of HIV‐1 gp120 that induce T cell apoptosis and block cell death induced by gp120 | |
US7070991B2 (en) | Cells expressing a CD4-IgG2 chimeric heterotetramer | |
US20030211470A1 (en) | CD4-IgG2-based salvage therapy of HIV-1 infection | |
AU623924B2 (en) | Cytotoxic agent against specific virus infection | |
WO1990000566A1 (fr) | Inhibition d'infection par vih-1 a l'aide de cd4 soluble | |
AU611551C (en) | Cloned genes encoding IG-CD4 fusion proteins and the use thereof | |
Agentsa | Implications for the Design of Small-Peptide | |
JP2009082135A (ja) | Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ | |
JPH03504802A (ja) | 特定のウイルス感染に対する細胞毒性剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |